MGMT promoter methylation

These findings emphasize the prognostic relevance of integrating molecular markers with traditional clinical and histopathological variables. This approach may enhance the precision of survival predictions and inform personalized therapeutic strategies in glioma management.

MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A/B status and extent of resection were strong predictors of outcomes.

Noninvasive imaging parameters extracted from QSM images can reflect glioma WHO grade, molecular markers, prognosis, and recurrence risk. These preliminary findings showed that the QSM might be a noninvasive imaging biomarker for comprehensive evaluation of adult-type diffuse gliomas.

P1, N=27, Recruiting, Washington University School of Medicine | N=12 --> 27

Both pre- and postoperative models successfully predict short-term recurrence in elderly glioma patients. Key clinical risk factors, such as tumors infiltrating the corpus callosum and various tumor-related symptoms were identified. Additionally, certain common postoperative physical and psychological symptom changes in the MDASI-BT may be predictive markers for long-term relapse. A crucial finding is that the factors associated with recurrence are distinct across molecular subtypes, underscoring the need for subtype-specific risk management.

The identified qMSP cut-off value (0.242) based on the procedure described in this study provides a robust prognostic stratification tool for GBM patients. High MGMT methylation correlates with improved survival, supporting its integration into clinical decision-making. Further multi-center validation studies are warranted to establish standardized MGMT assessment methodologies.

Future directions include a larger GBM Study allowing multivariable analysis, and other solid, potentially curable, cancer studies, where we envisage providing a Mn threshold to aid clinicians' decision making.

The accurate prediction of MGMT promoter methylation status via non-invasive imaging provides a reliable criterion for anticipating patient responsiveness to alkylating chemotherapy. This capability equips clinicians with a tool to inform personalized treatment strategies, optimizing therapeutic efficacy from the outset.

Our federated multi-task deep learning model demonstrates the feasibility and effectiveness of predicting glioma molecular characteristics and grade from multi-parametric MRI, without compromising patient privacy. These findings suggest significant potential for clinical deployment, especially in scenarios where invasive tissue sampling is impractical or risky.

We assessed drug use at baseline and defined 3 landmarks: start of temozolomide maintenance cycles 1 (landmark 1) and 4 (landmark 2), and end of cycle 6 (landmark 3)...Translational research studies should explore whether PPI-induced activity of ALDH mediates the potential adverse effects of PPI in glioblastoma. .

P2/3, N=144, Active, not recruiting, Laminar Pharmaceuticals | Trial completion date: May 2025 --> Nov 2026 | Trial primary completion date: Oct 2024 --> Jan 2026

P=N/A, N=18, Suspended, Royal Adelaide Hospital | Recruiting --> Suspended